PMID- 28064447
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20220311
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 6
IP  - 2
DP  - 2017 Feb
TI  - Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells 
      by targeting mTOR/Bcl-2.
PG  - 452-462
LID - 10.1002/cam4.987 [doi]
AB  - The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a 
      major burden for patients suffering from glioma. Recently, studies have 
      demonstrated that microRNAs play an important role in the regulation of tumor 
      properties in cancers. However, whether miR-497 contributes to glioma resistance 
      to chemotherapy is not fully understood. In this study, we showed that the 
      expression of miR-497 was markedly up-regulated in TMZ-resistant glioma cells; 
      high miR-497 expression level was associated with TMZ-resistant phenotype of 
      glioma cells. The down-regulation of miR-497 in glioma cells enhanced the 
      apoptosis-induction and growth inhibition effects of TMZ both in vitro and in 
      vivo, whereas promotion of miR-497 increased the chemosensitization of glioma 
      cells to TMZ. The increased level of miR-497 in TMZ-resistant glioma cells was 
      concurrent with the up-regulation of insulin-like growth factor 1 receptor 
      (IGF1R)/insulin receptor substrate 1 (IRS1) pathway-related proteins, that is, 
      IGF1R, IRS1, mammalian target of rapamycin (mTOR), and Bcl-2. In addition, the 
      knockdown of mTOR and Bcl-2 reduced the tolerance of glioma cells to TMZ. Our 
      results demonstrated that overexpression of miR-497 is significantly correlated 
      with TMZ resistance in glioma cells by regulating the IGF1R/IRS1 pathway. 
      Therefore, miR-497 may be used as a new target for treatment of 
      chemotherapy-resistant glioma.
CI  - (c) 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Zhu, Danhua
AU  - Zhu D
AD  - Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 
      188 Shizi Street, Canglang District, Suzhou, Jiangsu, 215000, China.
AD  - Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, Zhejiang, 325000, China.
FAU - Tu, Ming
AU  - Tu M
AD  - Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, Zhejiang, 325000, China.
FAU - Zeng, Bo
AU  - Zeng B
AD  - Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, Zhejiang, 325000, China.
FAU - Cai, Lin
AU  - Cai L
AD  - Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, Zhejiang, 325000, China.
FAU - Zheng, Weiming
AU  - Zheng W
AD  - Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, Zhejiang, 325000, China.
FAU - Su, Zhipeng
AU  - Su Z
AD  - Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, Zhejiang, 325000, China.
FAU - Yu, Zhengquan
AU  - Yu Z
AD  - Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 
      188 Shizi Street, Canglang District, Suzhou, Jiangsu, 215000, China.
LA  - eng
PT  - Journal Article
DEP - 20170108
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (BCL2 protein, human)
RN  - 0 (MIRN497 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Animals
MH  - Antineoplastic Agents, Alkylating/pharmacology
MH  - Apoptosis
MH  - Brain Neoplasms/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Dacarbazine/analogs & derivatives/pharmacology
MH  - *Drug Resistance, Neoplasm
MH  - Gene Expression Regulation, Neoplastic
MH  - Glioma/*genetics/pathology
MH  - Humans
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/*genetics
MH  - Temozolomide
MH  - *Up-Regulation
PMC - PMC5313645
OTO - NOTNLM
OT  - IGF1R/IRS1 pathway
OT  - microRNA
OT  - proliferation
OT  - tumor biology
EDAT- 2017/01/09 06:00
MHDA- 2017/11/29 06:00
PMCR- 2017/01/08
CRDT- 2017/01/09 06:00
PHST- 2016/08/27 00:00 [received]
PHST- 2016/10/27 00:00 [revised]
PHST- 2016/11/07 00:00 [accepted]
PHST- 2017/01/09 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/01/09 06:00 [entrez]
PHST- 2017/01/08 00:00 [pmc-release]
AID - CAM4987 [pii]
AID - 10.1002/cam4.987 [doi]
PST - ppublish
SO  - Cancer Med. 2017 Feb;6(2):452-462. doi: 10.1002/cam4.987. Epub 2017 Jan 8.